Loxenil Indications/Uses

Treatment of the following infections caused by susceptible strains of the designated microorganisms. Linezolid is not indicated for the treatment of gram-negative infections. It is critical that specific gram-negative therapy may be initiated immediately if a concomitant gram-negative pathogen is documented or suspected.
Vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia. Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae including multidrug resistant trains (MDRSP)]. Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. Linezolid has not been studied in the treatment of decubitus ulcers.
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes.
Community-acquired pneumonia caused by Streptococcus pneumoniae [including multidrug resistant strains {MDRSP)*], including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Linezolid and other antibacterial drugs, Linezolid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
*MDRSP refers to isolates resistant to ≥2 of the following antibiotics: Penicillin, 2nd-generation cephalosporins, macrolides, tetracycline and trimethoprim/sutfamethoxazole.